The type of studies to be included in this umbrella review is pretty heterogeneous in many senses. First, any type of comparator can be included though only studies based on aliskiren monotherapy are selected. Second, the types of study outcomes are also very heterogeneous and not very well defined. The authors should focus on more specific endpoints (e.g. BP response). How do they know in advance which outcomes are available from the different studies? I am afraid that this work will not return very relevant information. Rather, an updated meta-analysis of all published studies is a more robust approach.
English style needs revision.
VERSION 1 -AUTHOR RESPONSE
Dear Prof. James Coulson, I am very grateful to your comments for the manuscript. They are of great importance to us and our article. According to your advice, we amended the relevant part in manuscript. Some of your questions are answered below. 1. The date for including published papers is the inception of three databases (Pubmed, Cochrane and Embase). We have added in our article (line 34, page 1 and line 132, page 5) following your instructions.
2. Under your advice, we will grade our outcome. We will define some important cardiovascular outcomes (mortality rate, the composite of death and major adverse events, the incidence of stroke and myocardial infarction) as our primary outcome. We will define some other cardiovascualr outcomes (Changes of heart failure surrogate markers), renal effects, antihypertesive results as our secondary outcomes (line 181 -194, page 6). 3. Under your advice, we will divide patients into various groups, accroding to their different characteristics, in response to different outcomes. For example, when evaluating renal outcomes, we will divide patients into three groups: simple hypertension patients, patients with hypertension and diabetes; patients who are suffered from hypertension, diabetes and nephropathy or albuminuria at the same time. When evaluating antihypertensive effects, we will divide patients in three groups: young patients(<50y)early elderly patients (50-70y), elderly patients(> 70y) (line 211-221, page 7). 4. This is a very valuable recommendation, we didn't think about it before. We will add the costeffectiveness in our protocol, and treat it as an important outcome indicator in our future research (line 193-194 ,page 6 and line 230-237, page 7). 5. We have modified grammatical and syntax errors in our article carefully, with the help of a native English speaker Dear Prof. Stefano Omboni, I am very grateful to your comments for the manuscript. They are of great importance to us and our article. According with your advice, we amended the relevant part in manuscript. Some of your questions are answered below. 1. Publication of a protocol for a review that is written without knowledge of the available studies is important and necessary. It reduces the impact of review authors' biases, promotes transparency of methods and processes, reduces the potential for duplication, allows peer review of the planned methods before they have been completed, and offers an opportunity for the review team to plan resources and logistics for undertaking the review itself. Similarly the case for a protocol for a randomized trial, changes in a review protocol are sometimes necessary. It is important, however, that changes in the protocol should not be made on the basis of how they affect the outcome of the research study. Post hoc decisions made when the impact on the results of the research is known, such as excluding selected studies from a review, are highly susceptible to bias and should be avoided. A number of journals including BMJ Open, Trial, and international organizations such as the Cochrane Collaboration, Joanna Briggs Institute and Centre for Reviews &Dissemination have contributed to protocol publication. 2. About the heterogeneity of the article, our included systematic reviews are only integrations of randomized controlled trials (line 32, page 1; line 120, page5 and line 230-237, page 7). We will also do different sub-group analyses. For example, we will stratify the comparisons into different groups according to different drug doses, or categories of contrast drugs (line 206-210, page 7). In the changes, we will add in other sub-group analyses according to characteristics of different participants (e.g. diabetics or the age) (line 211-221, page 7). For each outcome, we will check if the random model was used, if not, we will extract data and estimate 95% CI using random effects methods by ourselves (line 40-41, page 1 and line 220-224, page 7). We will also use AMSTAR2 tool to evaluate quality of studies that we included (line 243-250, page 8). We will carefully consider the quality of evidence when interpreting the results (line 268-269, page 8). Why do we know in advance what results are available from different articles? If the systematic reviews have no outcome which we interest, the reviews will be excluded according our protocol. Our outcome measures include three components: cardiovascular, renal effects, and antihypertensive effects. Each big component will be divided into several specific small points. For example, under the effect of lowering blood pressure, specific points such as blood pressure reduction, blood pressure response rate, blood pressure control rate, and incidence of adverse effects are included (line 180-194, page 6). We will include outcome indicators as comprehensive as possible. 3. Reviews of systematic reviews called as umbrella reviews, overviews of reviews, reviews of reviews, a summary of systematic reviews and also a synthesis of reviews. The principle reason for conducting Umbrella Review is to summarize evidence from many research syntheses(Becker LA, Oxman AD 2010.Cochrane Handbook for Systematic Reviews of Interventions).These may include analyses of evidence of different interventions for the same problem or condition, evidence from more than one systematic review of the same intervention for different conditions or problems or populations, or evidence from more than one research synthesis investigating the same intervention and condition but addressing and reporting on different outcomes. Umbrella Review is to provide a summary of existing research syntheses related to a given topic or question and not to re-synthesize, for example, the results of existing reviews or syntheses with meta-analysis or meta-synthesis. Why we did an umbrella review? (1) Considering the large numbers of systematic reviews and research syntheses available to inform many topics in health care, systematic reviews of existing reviews are now being undertaken to compare and contrast published reviews and to provide an overall examination of a body of information that is available for a given topic. Conduct of our Umbrella Review offers the possibility of addressing a broad scope of issues related to aliskiren monotherapy. Our umbrella review will summarize evidence from more than one systematic review of different pharmaceutical drugs comparing aliskiren for different clinical outcomes (cardiovascular, renal and antihypertensive effects), and summarize evidence about adverse effects of aliskiren monotherapy from more than one systematic review of the use of this intervention for several different conditions.
(2) Decision makers are increasingly required to make evidence informed policy decisions and often require evidence in short timeframes. Our umbrella review is to serve as a "friendly front end", allowing the reader a quick overview (and an exhaustive list) of intervention reviews relevant to a specific decision. The primary audiences envisioned are decision makers (such as a clinicians, policy makers, or informed consumers) who are accessing for evidence on a specific problem (efficacy and safety of aliskiren monotherapy).
(3) If multiple, good quality, systematic reviews exist about a given topic or question, any reviewer should reconsider the need to conduct yet another review addressing the same issue. However, reviews about aliskiren monotherapy may not sufficient enough, or may not be of high quality, these may be the basis to conduct an Umbrella Review and summarize or synthesize the findings of systematic reviews already available. 4. We have modified English style of our article carefully, with the help of a native English speaker.
VERSION 2 -REVIEW

REVIEWER
Dr James Coulson Cardiff University, UK.
REVIEW RETURNED
11-Dec-2019
GENERAL COMMENTS
Thank you for addressing my previous comments. I have no further comments.
REVIEWER
Stefano Omboni
Italian Institute of Telemedicine REVIEW RETURNED 14-Dec-2019
GENERAL COMMENTS
The authors have modifed the paper addressing my remarks. They have better specified the study outcomes and they have added subgroup analysis. There are still grammatical errors and typos.
VERSION 2 -AUTHOR RESPONSE
Dear Prof. James Coulson, Thank you very much for your kind work and constructive suggestions on our paper. On behalf of my co-authors, we would like to express our great appreciation to you.
Dear Prof. Stefano Omboni, According with your advice, we amended the grammatical errors and typos of our study. We sought the help of an English-speaking scholar, who read our article word for word, helped us find several errors and changed them carefully. These changes will not influence the content and framework of our paper. Revised portion are marked red in the paper. We appreciate for your warm work earnestly, and hope that the corrections will meet with approval.
